Key Prostate Motion Management Experience Using the Calypso(R) Medical’s 4D Localization System(TM) To Be Presented at the 50th Annual Meeting of the AAPM
Calypso Medical Technologies, Inc. (Calypso Medical) today announced that eight new abstracts will be presented on prostate motion management in radiation therapy using the Calypso(R) 4D Localization System (Calypso System) at the AAPM annual scientific meeting July 27-31, 2008 in Houston, Texas. These scientific abstracts summarize clinical experiences with the first commercial installations of the Calypso System in radiation therapy.
The Calypso System is the only product platform that provides real-time tumor tracking during radiation treatment. This information is critical in assuring the clinician and the patient that the radiation treatment prescribed is delivered to the cancerous tissue while avoiding adjacent healthy organs. Known as GPS for the Body(R), the Calypso System utilizes implanted Beacon(R) electromagnetic transponders smaller than a grain of rice to enable continuous tracking of the prostate during radiation treatment.
“We are extremely pleased to have such rapid adoption of this technology in its first year and a half of commercialization. The Calypso System is being used in more than fifty leading cancer centers across the nation and more than 1,500 prostate cancer patients have benefited from this technology in a very short period of time. Patients are seeking out sites that offer GPS for the Body(R) technology. The patients we have talked with consider this technology to be a critical component of their treatment success,” says Eric R. Meier, CEO and President.
Calypso Medical will feature motion management solutions at Booth 100, including its most recent product upgrades for Beam On Reporting, Workflow Efficiency Enhancements and work-in-progress new system release for motion management; Adaptive Couch Repositioning and Motion Analysis Trend Reporting. The company will also highlight investigational pre-clinical studies underway for breast and lung cancer applications using the Calypso System.
Additionally, in May 2008 the U.S. Food and Drug Administration (FDA) cleared a new indication for the use of implantable Beacon(R) electromagnetic transponders for use in patients who have had a prostatectomy for follow-on external beam radiation therapy. Radiation therapy is the standard of care for patients with a high risk of prostate cancer recurrence or those in whom recurrence has been diagnosed. Studies indicate up to 40% of prostatectomy patients are diagnosed with recurrent prostate cancer following surgery and require radiation therapy.
The Calypso System will be highlighted in eight abstracts utilizing the technology to manage prostate motion on-line and off-line including an oral presentation by Dale W. Litzenberg, Ph.D. from the University of Michigan. The presented abstracts will be published in the (August 2008 Vol. 25, Issue 8) issue of the journal Medical Physics and include:
Predictability of Patient Specific Margins from Real-Time Intrafraction Motion Measurements D. Litzenberg, et al, University of Michigan, Ann Arbor, Mich. Wednesday, July 30, 4:00 p.m., Auditorium C Analysis of Prostate Patient Setup Error and Organ Motion Error Using Calypso Setup Shift and Tracking Data Z.Su, et al, Virginia Commonwealth University, Richmond, Va. Sunday, July 27, 1:30 p.m., Exhibit Hall 3 Comparison of CBCT and Electromagnetic Transponders for Prostate Localization J. Tanyi, et al, Oregon Health and Science University, Portland, Ore. Sunday, July 27, 2:15 p.m., Exhibit Hall 3 The Accuracy and Stability of the Calypso System for Prostate Localization and Motion Tracking J. Li, et al, Fox Chase Cancer Center, Philadelphia, Pa. Sunday, July 27, 3:00 p.m., Exhibit Hall Dosimetry Impact of Radiation Beams Due to Presence of Calypso Electromagnetic Array S. Li, et al, University of Nebraska Medical Center, Omaha, Neb. Sunday, July 27, 3:00 p.m., Exhibit Hall Real Time Tracking of Inter Marker Distances to Assess Maker Stability, Organ Deformation in Prostate Cancer A. Mahadevan, et al, Cleveland Clinic Foundation, Cleveland, Ohio Sunday, July 27, 3:00 p.m., Exhibit Hall Assessment of Conebeam CT Image Quality in the Presence of an Electromagnetic Tracking System L. Santanam, et al, Washington University School of Medicine, St. Louis, Mo. Sunday, July 27, 3:00 p.m., Exhibit Hall Geometric Uncertainty Caused by Prostate Rotation During Radiotherapy L Jin, et al, Fox Chase Cancer Center, Philadelphia, Pa. Sunday, July 27, 3:00 p.m., Exhibit Hall
About Calypso(R) Medical
Calypso Medical Technologies, Inc. (“Calypso”) is a Seattle, WA-based privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon(R) electromagnetic transponders) to continuously, accurately, and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso(R) 4D Localization System’s non-ionizing electromagnetic guidance has been found to improve work flow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. The products are FDA 510(k) cleared for use in the prostate and prostatic bed. Additional information can be found at www.calypsomedical.com.